Adefovir Dipivoxil
Acute Liver Failure
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculeUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Acute Liver Failure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylcysteine Azienda Ospedaliera di Padova | Phase 3 | BB |
Emricasan Conatus Pharmaceuticals Inc. | Phase 2 | CCC |
Lamivudine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | D |
HEPABULIN National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | D |
Same molecule, other indications
Adefovir Dipivoxil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →